TCGA-AO-A0JA-01A-11R-A056-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 22
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.420
- PROTEIN_SECRETION+0.410
- UV_RESPONSE_DN+0.400
- MITOTIC_SPINDLE+0.360
- TGF_BETA_SIGNALING+0.350
- APICAL_JUNCTION+0.320
- COAGULATION+0.320
- HEDGEHOG_SIGNALING+0.310
- COMPLEMENT+0.280
- ANGIOGENESIS+0.270
Top 10 suppressed
- MYC_TARGETS_V2-0.580
- OXIDATIVE_PHOSPHORYLATION-0.300
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.230
- KRAS_SIGNALING_DN-0.210
- MTORC1_SIGNALING-0.180
- IL6_JAK_STAT3_SIGNALING-0.170
- HYPOXIA-0.160
- DNA_REPAIR-0.140
- GLYCOLYSIS-0.140
- MYC_TARGETS_V1-0.120
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-AR-A24M-01A-11R-A169-07 | — | B | 0.780 |
| 2 | SRR5088836 | — | — | 0.765 |
| 3 | TCGA-AQ-A1H3-01A-31R-A13Q-07 | — | A | 0.765 |
| 4 | TCGA-55-6642-01A-11R-1858-07 | — | cohortA3 | 0.757 |
| 5 | TCGA-DK-A2HX-01A-12R-A18C-07 | — | — | 0.756 |
| 6 | TCGA-91-6829-01A-21R-1858-07 | — | cohortA1 | 0.755 |
| 7 | TCGA-44-6775-01A-11R-A278-07 | — | cohortMD2 | 0.751 |
| 8 | SAMN03290934 | — | — | 0.749 |
| 9 | TCGA-64-1679-01A-21R-2066-07 | — | cohortA1 | 0.746 |
| 10 | f5e6497a-ed39-408d-9034-a965baaafbf7 | — | — | 0.745 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.420 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.410 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.400 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.360 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.350 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.320 | Inavolisib | — uncovered |
| COAGULATION | 0.320 | Binimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.310 | Inavolisib | — uncovered |
| COMPLEMENT | 0.280 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.270 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.250 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.230 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.210 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.210 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.200 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.190 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.170 | Inavolisib | — uncovered |
| MYOGENESIS | 0.160 | Inavolisib | — uncovered |
| APOPTOSIS | 0.150 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.110 | Idelalisib | — uncovered |